scorecardresearch
Add as a preferred source on Google
Sunday, November 30, 2025
TopicVaccine

Topic: Vaccine

Not Oxford lab, not US company, Covid solution will come from India, China pharma industry

Fast and mass pharma production in India and China is crucial if the coronavirus pandemic is to be brought under control.

Are people who have had Covid-19 immune? Perhaps not

What needs to happen now is a series of studies to determine whether the presence of antibodies is associated with protection against re-infection with SARS-CoV-2.

Covid vaccine makers may need to infect subjects to get results

As the infection rate changes, companies running drug trials will face a new problem — not enough test subjects in their regions.

Indian vaccine ventures with global partners could move to human trials soon: VijayRaghavan

At least 14 vaccine candidates being developed solely by Indian players, but none ready for human trials stage yet, Principal Scientific Adviser K. VijayRaghavan says.

Why vaccines should not be immune to market forces

Market prices for vaccines could ensure additional production, help differentiate between vaccines, and even allocation of resources.

Green shoots emerge in world economy as virus lockdowns ease

Indicators such as electricity demand and traffic congestions point to a modest 'lift of lows', as economic recovery remains uneven in the absence of a vaccine.

There will be more than one coronavirus vaccine, and that will be a merry situation

With over 70 vaccine candidates, the end of the Covid crisis will likely be multiple vaccines, some more traditional and others based on emerging technologies.

US pharma giant Merck hopes to beat coronavirus with a pill and two vaccines

Merck bought rights to develop a promising antiviral and will work with partners to advance candidate vaccines based on the technology behind Ebola and measles immunizations.

Xi Jinping is seeking to beat Trump in the race for a coronavirus vaccine

China has promised to share any successful vaccine globally, and would wield immense geopolitical clout if it produces one of the world’s first working shots.

Chinese vaccine shows promise in early human trial, generates immune response against Covid

The vaccine developed by CanSino Biologics is the first candidate to be tested in human trials.

On Camera

‘Delhi winters’ is a legend. Now it’s just air anxiety

The wealthy float above the crisis—insulated in air-purified cars, weekend getaways at farmhouses, and vacations timed perfectly to coincide with Delhi’s worst weeks.

Karnataka startups feel the chill as global funding winter sets in. Fintech emerges as sole bright spot

The state raises just $2.7 billion in first nine months of 2025 compared to $4.5 billion last year, with late-stage investments hit hardest.

What’s expected from Putin’s India visit in December—Defence Secretary explains

ThePrint had previously reported that India & Russia are talking about 5 more regiments of the S-400, but no contracts are to be signed during the Russian president's visit.

Gaali cricket: Bavuma stands tall, India’s Test ego cut to size

The India-South Africa series-defining fact is the catastrophic decline of Indian red ball cricket where a visiting team can mock us with the 'grovel' word.